Gilead Sciences (GILD) Other Accumulated Expenses (2011 - 2026)

Gilead Sciences (GILD) has 12 years of Other Accumulated Expenses data on file, last reported at $3.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 26.35% year-over-year to $3.4 billion; the trailing twelve-month figure through Mar 2026 stood at $3.4 billion (down 26.35% YoY), and the FY2025 full-year result was $4.0 billion, down 27.65% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $3.4 billion, down from $4.0 billion in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $5.9 billion in Q3 2023 and bottomed at $3.4 billion in Q1 2026.
• The 5-year median for Other Accumulated Expenses is $4.5 billion (2022), against an average of $4.6 billion.
• The widest annual swing landed in 2023, when Other Accumulated Expenses increased 12.01%; it then slipped 27.65% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $4.6 billion in 2022, then gained by 12.01% to $5.1 billion in 2023, then rose by 6.51% to $5.5 billion in 2024, then fell by 27.65% to $4.0 billion in 2025, then retreated by 14.01% to $3.4 billion in 2026.
• The last three Other Accumulated Expenses figures came in at $3.4 billion (Q1 2026), $4.0 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.

Peer Comparison